Last $20.88 USD
Change Today -0.30 / -1.42%
Volume 207.7K
NLNK On Other Exchanges
As of 8:10 PM 08/1/14 All times are local (Market data is delayed by at least 15 minutes).

newlink genetics corp (NLNK) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/25/14 - $53.48
52 Week Low
09/11/13 - $15.61
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NEWLINK GENETICS CORP (NLNK)

newlink genetics corp (NLNK) Related Bloomberg News

View More Bloomberg News

newlink genetics corp (NLNK) Related Businessweek News

No Related Businessweek News Found

newlink genetics corp (NLNK) Details

NewLink Genetics Corporation, a biopharmaceutical company, focuses on discovering, developing, and commercializing immunotherapeutic products to enhance treatment options for patients with cancer. Its portfolio includes biologic product candidates based on its HyperAcute immunotherapy technology, which is designed to stimulate the human immune system; and small-molecule product candidates that are focused on breaking the immune system's tolerance to cancer by inhibiting the indoleamine-(2,3)-dioxygenase (IDO) pathway. The company’s lead product candidate, HyperAcute Pancreas immunotherapy that is being studied in Phase III clinical trials in surgically-resected pancreatic cancer patients, as well as in patients with advanced pancreatic cancer. It is also developing HyperAcute Lung immunotherapy for non-small cell lung cancer; HyperAcute Melanoma immunotherapy for the treatment of patients with advanced melanoma; and HyperAcute Renal cell cancer immunotherapy product candidate, as well as HyperAcute prostate cancer and HyperAcute breast cancer immunotherapy product candidates. In addition, the company is developing IDO pathway inhibitors comprising indoximod, a small-molecule, orally bioavailable product candidate, which is being studies in metastatic breast cancer, as well as a therapy after sipuleucel-T treatment in metastatic castrate-resistant prostate cancer; and NLG919 for patients with solid tumors. NewLink Genetics Corporation was founded in 1999 and is headquartered in Ames, Iowa.

104 Employees
Last Reported Date: 03/12/14
Founded in 1999

newlink genetics corp (NLNK) Top Compensated Officers

Founder, Chairman, Chief Executive Officer an...
Total Annual Compensation: $540.8K
President, Chief Operations Officer and Chief...
Total Annual Compensation: $420.0K
Chief Financial Officer and Secretary
Total Annual Compensation: $286.6K
Clinical & Regulatory Compliance Officer and ...
Total Annual Compensation: $283.8K
Vice President of Business Development
Total Annual Compensation: $250.0K
Compensation as of Fiscal Year 2013.

newlink genetics corp (NLNK) Key Developments

Newlink Genetics Corporation Announces Data from Phase 2 Clinical Study of its Dorgenmeltucel-L Hyperacute Immunotherapy

NewLink Genetics Corporation announced data from a Phase 2 clinical study of its dorgenmeltucel-L HyperAcute immunotherapy in combination with pegylated interferon-alpha 2b in patients with advanced metastatic, progressive, refractory or recurrent melanoma. The study will be featured in the upcoming edition of The Ochsner Journal, Volume 14, Number 2, Summer 2014, Academic Division of Ochsner Clinic Foundation. The treatment regimen consisted of 12 weekly vaccinations with 150 million cell dosage of dorgenmeltucel-L in combination with short course, pegylated interferon-alpha 2b given during weeks 5 through 12. These data demonstrated that the combination was capable of inducing complete and durable clinical responses with tumor regression and immune activation. The study enrolled 25 patients, 21 of which completed the trial and were evaluable for response. The upcoming publication will highlight that of the 16 patients with stage IV disease, two had a complete response (CR) per Response Evaluation Criteria in Solid Tumors (RESIST), one had stable disease (SD), and four had no evidence of disease (NED) after resection. Furthermore, of the nine patients with stage II/III disease, three remained NED, and one stage IIC patient had slow progressive disease (PD) with a single site resected, this patient is currently NED. The median overall survival was 29 months, with 60% of the patients surviving for longer than one year. Of the 25 patients enrolled, 12 (48%) were still alive. All evaluable patients (21/21) seroconverted, developing autoimmune antibodies. Importantly, 4 of 25 patients developed vitiligo, correlating with two CR patients by RECIST criteria and two NED patients. Dorgenmeltucel-L HyperAcute immunotherapy in combination with pegylated interferon-alpha 2b was shown to be safe and well-tolerated in this study with no serious adverse events reported.

NewLink Genetics Corporation Presents at Jefferies 2014 Global Healthcare Conference, Jun-04-2014 03:00 PM

NewLink Genetics Corporation Presents at Jefferies 2014 Global Healthcare Conference, Jun-04-2014 03:00 PM. Venue: Grand Hyatt, New York, New York, United States. Speakers: Charles J. Link, Founder, Chairman, Chief Executive Officer and Chief Scientific Officer.

NewLink Genetics Corporation Reports Unaudited Consolidated Financial Results for the First Quarter Ended March 31, 2014

NewLink Genetics Corporation reported unaudited consolidated financial results for the first quarter ended March 31, 2014. The company reported net loss of $9.2 million or $0.33 per basic and diluted share for the first quarter of 2014 compared to a net loss of $7.9 million or $0.33 per basic and diluted share for the comparable period in 2013. Grant revenue was $334,000, compared to $302,000 for the comparable period in 2013. Loss from operations was $9,304,000, compared to $8,042,000 for the comparable period in 2013.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NLNK:US $20.88 USD -0.30

NLNK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NLNK.
View Industry Companies

Industry Analysis


Industry Average

Valuation NLNK Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 519.7x
Price/Book 7.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 449.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEWLINK GENETICS CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at